| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rotavirus Vaccines | 6 | 2015 | 62 | 2.260 |
Why?
|
| Rotavirus Infections | 5 | 2015 | 85 | 1.850 |
Why?
|
| Papillomavirus Vaccines | 4 | 2022 | 497 | 1.620 |
Why?
|
| Levonorgestrel | 2 | 2022 | 78 | 1.530 |
Why?
|
| Pharmacoepidemiology | 7 | 2024 | 352 | 1.330 |
Why?
|
| Contraceptives, Oral, Combined | 6 | 2022 | 117 | 1.320 |
Why?
|
| Hypoglycemic Agents | 13 | 2019 | 3111 | 1.230 |
Why?
|
| Insurance Claim Review | 8 | 2022 | 745 | 1.160 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 1638 | 1.030 |
Why?
|
| Urinary Bladder, Overactive | 3 | 2024 | 117 | 1.020 |
Why?
|
| Control Groups | 3 | 2021 | 107 | 0.960 |
Why?
|
| Databases, Factual | 24 | 2023 | 8081 | 0.940 |
Why?
|
| Venoms | 4 | 2016 | 94 | 0.910 |
Why?
|
| Pancreatitis | 7 | 2019 | 1087 | 0.900 |
Why?
|
| Gastroenteritis | 3 | 2015 | 236 | 0.870 |
Why?
|
| International Classification of Diseases | 4 | 2023 | 925 | 0.810 |
Why?
|
| Cohort Studies | 56 | 2024 | 41797 | 0.790 |
Why?
|
| Vaccination | 11 | 2024 | 3434 | 0.770 |
Why?
|
| Intussusception | 2 | 2012 | 117 | 0.730 |
Why?
|
| Ethinyl Estradiol | 4 | 2010 | 114 | 0.700 |
Why?
|
| Drug Labeling | 4 | 2018 | 250 | 0.670 |
Why?
|
| Thiophenes | 3 | 2012 | 570 | 0.620 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 809 | 0.590 |
Why?
|
| Warfarin | 3 | 2017 | 1493 | 0.590 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2016 | 3253 | 0.580 |
Why?
|
| Abortion, Spontaneous | 1 | 2023 | 539 | 0.580 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 133 | 0.580 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 2959 | 0.580 |
Why?
|
| Rheumatic Diseases | 2 | 2020 | 664 | 0.570 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1884 | 0.570 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2022 | 3763 | 0.560 |
Why?
|
| Contraceptives, Oral | 3 | 2016 | 562 | 0.560 |
Why?
|
| Pericarditis | 3 | 2023 | 136 | 0.560 |
Why?
|
| Indoles | 4 | 2012 | 1834 | 0.560 |
Why?
|
| Stroke | 8 | 2021 | 9791 | 0.550 |
Why?
|
| United States | 59 | 2024 | 73121 | 0.550 |
Why?
|
| Off-Label Use | 2 | 2014 | 186 | 0.500 |
Why?
|
| Drug Prescriptions | 6 | 2017 | 1677 | 0.500 |
Why?
|
| Immunity, Herd | 1 | 2015 | 48 | 0.490 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2016 | 246 | 0.470 |
Why?
|
| Diabetes Mellitus | 5 | 2020 | 5887 | 0.470 |
Why?
|
| Propensity Score | 10 | 2017 | 1971 | 0.470 |
Why?
|
| Drug Information Services | 1 | 2014 | 51 | 0.460 |
Why?
|
| Adolescent | 45 | 2024 | 89168 | 0.460 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1145 | 0.460 |
Why?
|
| Female | 100 | 2024 | 396943 | 0.450 |
Why?
|
| Hemorrhage | 2 | 2017 | 3458 | 0.450 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2016 | 182 | 0.450 |
Why?
|
| Antirheumatic Agents | 3 | 2020 | 1374 | 0.450 |
Why?
|
| Congenital Abnormalities | 2 | 2016 | 708 | 0.440 |
Why?
|
| Humans | 142 | 2024 | 768451 | 0.430 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 110 | 0.430 |
Why?
|
| Hypercholesterolemia | 5 | 2005 | 1142 | 0.430 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 116 | 0.420 |
Why?
|
| Acetanilides | 3 | 2024 | 169 | 0.420 |
Why?
|
| Contraception | 2 | 2016 | 362 | 0.410 |
Why?
|
| Thrombophilia | 1 | 2015 | 306 | 0.410 |
Why?
|
| Stillbirth | 1 | 2016 | 376 | 0.410 |
Why?
|
| Young Adult | 29 | 2023 | 60045 | 0.410 |
Why?
|
| Male | 90 | 2024 | 364781 | 0.410 |
Why?
|
| Circovirus | 1 | 2012 | 3 | 0.400 |
Why?
|
| Live Birth | 1 | 2016 | 516 | 0.400 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 1487 | 0.400 |
Why?
|
| Analgesics | 1 | 2019 | 1070 | 0.400 |
Why?
|
| Peptides | 4 | 2016 | 4368 | 0.400 |
Why?
|
| Incidence | 15 | 2024 | 21552 | 0.390 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2012 | 151 | 0.390 |
Why?
|
| Insurance, Health | 8 | 2019 | 2513 | 0.390 |
Why?
|
| Androstenes | 3 | 2008 | 186 | 0.390 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2012 | 143 | 0.390 |
Why?
|
| Guideline Adherence | 5 | 2013 | 2239 | 0.380 |
Why?
|
| Aprotinin | 2 | 2008 | 94 | 0.380 |
Why?
|
| Drug Approval | 3 | 2017 | 817 | 0.380 |
Why?
|
| Insulin | 5 | 2018 | 6606 | 0.370 |
Why?
|
| Adult | 62 | 2024 | 223542 | 0.370 |
Why?
|
| Myocardial Infarction | 9 | 2016 | 11515 | 0.370 |
Why?
|
| United States Food and Drug Administration | 6 | 2015 | 1669 | 0.360 |
Why?
|
| Quinoxalines | 1 | 2013 | 297 | 0.360 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 266 | 0.360 |
Why?
|
| Myocarditis | 3 | 2023 | 804 | 0.360 |
Why?
|
| Benzazepines | 1 | 2013 | 311 | 0.360 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2243 | 0.360 |
Why?
|
| Infant | 21 | 2024 | 36497 | 0.360 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 975 | 0.360 |
Why?
|
| Bupropion | 1 | 2012 | 304 | 0.360 |
Why?
|
| Drug Contamination | 1 | 2012 | 152 | 0.360 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 286 | 0.360 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2723 | 0.360 |
Why?
|
| Epidemiologic Methods | 2 | 2013 | 1337 | 0.350 |
Why?
|
| Anticoagulants | 2 | 2017 | 4840 | 0.350 |
Why?
|
| Cholecystectomy | 1 | 2012 | 409 | 0.350 |
Why?
|
| Dermatitis, Atopic | 2 | 2009 | 734 | 0.350 |
Why?
|
| Norgestrel | 1 | 2010 | 11 | 0.350 |
Why?
|
| Risk Management | 2 | 2015 | 558 | 0.350 |
Why?
|
| Mitoxantrone | 1 | 2010 | 148 | 0.340 |
Why?
|
| Hypnotics and Sedatives | 2 | 2017 | 1188 | 0.340 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 490 | 0.330 |
Why?
|
| Insurance Benefits | 3 | 2016 | 187 | 0.320 |
Why?
|
| Thromboembolism | 3 | 2017 | 1006 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2018 | 12242 | 0.320 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 254 | 0.320 |
Why?
|
| Middle Aged | 57 | 2023 | 223418 | 0.320 |
Why?
|
| Propylamines | 1 | 2009 | 162 | 0.320 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 5 | 2008 | 495 | 0.310 |
Why?
|
| Migraine Disorders | 2 | 2019 | 1713 | 0.310 |
Why?
|
| Observation | 2 | 2007 | 311 | 0.310 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2011 | 617 | 0.300 |
Why?
|
| Receptor, erbB-2 | 1 | 2019 | 2586 | 0.300 |
Why?
|
| Erectile Dysfunction | 2 | 2022 | 445 | 0.300 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2008 | 65 | 0.300 |
Why?
|
| Pelvis | 1 | 2012 | 737 | 0.300 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 518 | 0.300 |
Why?
|
| Contraceptive Agents, Female | 1 | 2009 | 121 | 0.300 |
Why?
|
| Immunization Schedule | 1 | 2009 | 227 | 0.300 |
Why?
|
| Carotid Stenosis | 4 | 2016 | 864 | 0.300 |
Why?
|
| Pyridines | 2 | 2017 | 2888 | 0.300 |
Why?
|
| Drug Monitoring | 3 | 2010 | 964 | 0.290 |
Why?
|
| Fluoroquinolones | 2 | 2007 | 309 | 0.290 |
Why?
|
| Glucocorticoids | 2 | 2009 | 2170 | 0.290 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15638 | 0.290 |
Why?
|
| Tamoxifen | 1 | 2012 | 968 | 0.290 |
Why?
|
| Anaphylaxis | 3 | 2022 | 758 | 0.290 |
Why?
|
| Epidemiologic Research Design | 2 | 2016 | 368 | 0.290 |
Why?
|
| Aged | 49 | 2024 | 171520 | 0.280 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 286 | 0.280 |
Why?
|
| Insurance, Physician Services | 1 | 2006 | 23 | 0.280 |
Why?
|
| Thiazoles | 3 | 2024 | 1541 | 0.270 |
Why?
|
| Retrospective Studies | 32 | 2022 | 81834 | 0.270 |
Why?
|
| Abdomen | 1 | 2012 | 1136 | 0.270 |
Why?
|
| Vaccines, Attenuated | 3 | 2013 | 315 | 0.260 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 3237 | 0.260 |
Why?
|
| Infant, Newborn | 16 | 2017 | 26395 | 0.260 |
Why?
|
| Insurance Claim Reporting | 1 | 2006 | 166 | 0.260 |
Why?
|
| Risk Factors | 24 | 2021 | 74915 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 10358 | 0.250 |
Why?
|
| Hemostatics | 1 | 2008 | 246 | 0.250 |
Why?
|
| Comparative Effectiveness Research | 4 | 2016 | 712 | 0.250 |
Why?
|
| Sulfonylurea Compounds | 1 | 2007 | 220 | 0.250 |
Why?
|
| Ischemic Attack, Transient | 2 | 2016 | 878 | 0.250 |
Why?
|
| Tacrolimus | 1 | 2009 | 750 | 0.240 |
Why?
|
| Cholesterol, LDL | 3 | 2003 | 2396 | 0.240 |
Why?
|
| Gastrointestinal Agents | 1 | 2010 | 510 | 0.240 |
Why?
|
| Child | 26 | 2024 | 80863 | 0.240 |
Why?
|
| Patient Education as Topic | 3 | 2018 | 2339 | 0.240 |
Why?
|
| Lipids | 2 | 2005 | 3346 | 0.230 |
Why?
|
| Pregnancy | 8 | 2023 | 30179 | 0.230 |
Why?
|
| Achilles Tendon | 1 | 2006 | 181 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2024 | 463 | 0.230 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 462 | 0.220 |
Why?
|
| Metformin | 3 | 2013 | 914 | 0.220 |
Why?
|
| Pharmaceutical Services | 1 | 2005 | 143 | 0.220 |
Why?
|
| Premature Birth | 1 | 2016 | 1816 | 0.220 |
Why?
|
| Muscarinic Antagonists | 2 | 2021 | 135 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9263 | 0.220 |
Why?
|
| Follow-Up Studies | 19 | 2018 | 39430 | 0.220 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2003 | 190 | 0.220 |
Why?
|
| Medicare | 9 | 2024 | 6881 | 0.210 |
Why?
|
| Gout Suppressants | 2 | 2015 | 177 | 0.210 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 6527 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 4049 | 0.200 |
Why?
|
| Formularies as Topic | 1 | 2002 | 94 | 0.200 |
Why?
|
| Treatment Outcome | 25 | 2022 | 65409 | 0.200 |
Why?
|
| Smoking Cessation | 2 | 2018 | 2079 | 0.200 |
Why?
|
| Case-Control Studies | 8 | 2020 | 22293 | 0.200 |
Why?
|
| Drug Utilization | 3 | 2015 | 1192 | 0.200 |
Why?
|
| Managed Care Programs | 2 | 2007 | 941 | 0.200 |
Why?
|
| Endarterectomy, Carotid | 3 | 2016 | 558 | 0.190 |
Why?
|
| Child, Preschool | 17 | 2024 | 42623 | 0.190 |
Why?
|
| Health Services Research | 1 | 2009 | 1815 | 0.190 |
Why?
|
| Current Procedural Terminology | 1 | 2022 | 101 | 0.190 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 12561 | 0.190 |
Why?
|
| Cause of Death | 4 | 2016 | 3727 | 0.180 |
Why?
|
| Cellulitis | 1 | 2022 | 209 | 0.180 |
Why?
|
| Acute Disease | 5 | 2019 | 7246 | 0.170 |
Why?
|
| Marketing | 1 | 2022 | 224 | 0.170 |
Why?
|
| Heptanoic Acids | 2 | 2002 | 344 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 2538 | 0.170 |
Why?
|
| Narcolepsy | 1 | 2022 | 200 | 0.170 |
Why?
|
| Risk Assessment | 11 | 2016 | 24311 | 0.170 |
Why?
|
| Research Design | 4 | 2024 | 6217 | 0.170 |
Why?
|
| Cyclohexanols | 2 | 2012 | 126 | 0.170 |
Why?
|
| Lymphoma | 1 | 2009 | 1907 | 0.170 |
Why?
|
| Neoplasms | 3 | 2021 | 22386 | 0.170 |
Why?
|
| Confidence Intervals | 3 | 2011 | 2932 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2913 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 2139 | 0.160 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2020 | 160 | 0.160 |
Why?
|
| Depressive Disorder | 1 | 2012 | 3738 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3246 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 4213 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 21156 | 0.150 |
Why?
|
| Psoriasis | 1 | 2007 | 947 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2012 | 6410 | 0.150 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 156 | 0.150 |
Why?
|
| Incretins | 1 | 2019 | 100 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1734 | 0.150 |
Why?
|
| Pregnancy Trimester, First | 2 | 2012 | 918 | 0.150 |
Why?
|
| Arthritis, Psoriatic | 1 | 2020 | 220 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 5367 | 0.140 |
Why?
|
| Fertility | 1 | 2022 | 772 | 0.140 |
Why?
|
| Blood Glucose | 4 | 2018 | 6429 | 0.140 |
Why?
|
| Gout | 2 | 2015 | 621 | 0.140 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 716 | 0.140 |
Why?
|
| Hemophilia B | 1 | 2017 | 83 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 2012 | 2969 | 0.140 |
Why?
|
| Factor VIIa | 1 | 2017 | 103 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 5162 | 0.140 |
Why?
|
| Anticholesteremic Agents | 3 | 2000 | 972 | 0.140 |
Why?
|
| Stents | 4 | 2016 | 3204 | 0.140 |
Why?
|
| Logistic Models | 8 | 2013 | 13324 | 0.130 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 681 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1135 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 1183 | 0.130 |
Why?
|
| Pyrroles | 2 | 2002 | 1127 | 0.130 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 366 | 0.120 |
Why?
|
| Hyperkalemia | 2 | 2008 | 233 | 0.120 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2015 | 29 | 0.120 |
Why?
|
| Drug Hypersensitivity | 2 | 2007 | 922 | 0.120 |
Why?
|
| Asthma | 1 | 2014 | 6274 | 0.120 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 3245 | 0.120 |
Why?
|
| Algorithms | 4 | 2023 | 14158 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2008 | 1903 | 0.120 |
Why?
|
| Drug Evaluation | 2 | 2015 | 642 | 0.120 |
Why?
|
| Models, Statistical | 3 | 2014 | 5103 | 0.120 |
Why?
|
| Encyclopedias as Topic | 1 | 2014 | 19 | 0.120 |
Why?
|
| Defibrillators, Implantable | 2 | 2015 | 1498 | 0.120 |
Why?
|
| Insulin, Long-Acting | 1 | 2014 | 59 | 0.120 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 59680 | 0.120 |
Why?
|
| Hemophilia A | 1 | 2017 | 359 | 0.120 |
Why?
|
| Risk | 7 | 2017 | 9642 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 943 | 0.110 |
Why?
|
| Fetal Death | 1 | 2016 | 438 | 0.110 |
Why?
|
| Antithrombins | 1 | 2017 | 294 | 0.110 |
Why?
|
| Apolipoprotein A-I | 2 | 2005 | 305 | 0.110 |
Why?
|
| Hospitalization | 7 | 2022 | 10845 | 0.110 |
Why?
|
| Mortality | 2 | 2016 | 2917 | 0.110 |
Why?
|
| Sentinel Surveillance | 1 | 1996 | 292 | 0.110 |
Why?
|
| Colchicine | 1 | 2015 | 258 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2008 | 5926 | 0.110 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 643 | 0.110 |
Why?
|
| Problem Solving | 1 | 2016 | 443 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10784 | 0.110 |
Why?
|
| Benzoates | 1 | 2014 | 213 | 0.110 |
Why?
|
| Hypertension | 3 | 2022 | 8611 | 0.110 |
Why?
|
| Hydrazines | 1 | 2014 | 223 | 0.110 |
Why?
|
| Coronary Artery Bypass | 2 | 2015 | 2194 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 92 | 0.110 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 26351 | 0.110 |
Why?
|
| Mass Media | 1 | 2016 | 304 | 0.100 |
Why?
|
| Polypharmacy | 1 | 2015 | 307 | 0.100 |
Why?
|
| Thrombopoietin | 1 | 2014 | 226 | 0.100 |
Why?
|
| Allopurinol | 1 | 2014 | 198 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 7471 | 0.100 |
Why?
|
| Prevalence | 4 | 2019 | 15880 | 0.100 |
Why?
|
| Embolism | 1 | 2015 | 401 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2015 | 464 | 0.100 |
Why?
|
| HIV Infections | 6 | 2010 | 17564 | 0.100 |
Why?
|
| Comorbidity | 6 | 2015 | 10601 | 0.100 |
Why?
|
| Depression | 1 | 2011 | 8235 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 4861 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2013 | 1482 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2016 | 454 | 0.090 |
Why?
|
| Receptors, Fc | 1 | 2014 | 539 | 0.090 |
Why?
|
| Hyperuricemia | 1 | 2014 | 223 | 0.090 |
Why?
|
| Prospective Studies | 10 | 2020 | 54914 | 0.090 |
Why?
|
| Methotrexate | 3 | 2002 | 1722 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1536 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2002 | 2063 | 0.090 |
Why?
|
| Data Collection | 2 | 2013 | 3329 | 0.090 |
Why?
|
| Fructose | 1 | 2012 | 285 | 0.090 |
Why?
|
| Hospital Mortality | 3 | 2015 | 5371 | 0.090 |
Why?
|
| Thrombosis | 1 | 2024 | 2956 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2012 | 433 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2015 | 1568 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 254 | 0.080 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 1948 | 0.080 |
Why?
|
| Carbolines | 2 | 2022 | 296 | 0.080 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2010 | 38 | 0.080 |
Why?
|
| Electronic Health Records | 3 | 2022 | 4877 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2012 | 293 | 0.080 |
Why?
|
| Critical Care | 1 | 2022 | 2717 | 0.080 |
Why?
|
| Drug Industry | 1 | 2016 | 793 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 4362 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13708 | 0.080 |
Why?
|
| Cholesterol, HDL | 2 | 2005 | 1820 | 0.080 |
Why?
|
| Internationality | 1 | 2014 | 1007 | 0.080 |
Why?
|
| Office Visits | 1 | 2013 | 596 | 0.080 |
Why?
|
| Glyburide | 1 | 2009 | 117 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 1120 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 348 | 0.080 |
Why?
|
| Age Factors | 5 | 2016 | 18478 | 0.070 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 658 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12096 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2023 | 15460 | 0.070 |
Why?
|
| Comprehension | 1 | 2013 | 641 | 0.070 |
Why?
|
| National Health Programs | 1 | 2010 | 442 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 186 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2009 | 707 | 0.070 |
Why?
|
| Progesterone Congeners | 1 | 2006 | 44 | 0.070 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 540 | 0.070 |
Why?
|
| Postmenopause | 1 | 2016 | 2519 | 0.070 |
Why?
|
| Aging | 1 | 2005 | 8761 | 0.070 |
Why?
|
| Probability | 3 | 2014 | 2483 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2012 | 598 | 0.070 |
Why?
|
| Cholesterol | 2 | 2005 | 2910 | 0.070 |
Why?
|
| Skin Diseases, Infectious | 1 | 2006 | 76 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 2705 | 0.070 |
Why?
|
| Age Distribution | 2 | 2015 | 2881 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3735 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 6320 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2007 | 200 | 0.060 |
Why?
|
| Data Mining | 1 | 2010 | 561 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2016 | 1252 | 0.060 |
Why?
|
| Attention | 1 | 2016 | 2423 | 0.060 |
Why?
|
| Patient-Centered Care | 2 | 2013 | 1439 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2013 | 1189 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2016 | 1401 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 1460 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 2228 | 0.060 |
Why?
|
| Rheumatoid Factor | 1 | 2005 | 184 | 0.060 |
Why?
|
| Registries | 4 | 2016 | 8373 | 0.060 |
Why?
|
| Rupture | 1 | 2006 | 444 | 0.060 |
Why?
|
| Health Expenditures | 2 | 2016 | 2391 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2012 | 2206 | 0.060 |
Why?
|
| Soft Tissue Infections | 1 | 2006 | 168 | 0.060 |
Why?
|
| Antifibrinolytic Agents | 1 | 2008 | 289 | 0.060 |
Why?
|
| Triglycerides | 1 | 2012 | 2465 | 0.060 |
Why?
|
| Medical Records | 1 | 2010 | 1413 | 0.060 |
Why?
|
| Fluorobenzenes | 1 | 2006 | 179 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2014 | 1594 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 14766 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2014 | 2024 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2015 | 1946 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 2665 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2016 | 9382 | 0.060 |
Why?
|
| Naproxen | 1 | 2004 | 101 | 0.060 |
Why?
|
| Apolipoproteins B | 1 | 2005 | 386 | 0.060 |
Why?
|
| Economic Competition | 2 | 2016 | 223 | 0.050 |
Why?
|
| Penicillins | 1 | 2007 | 405 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2010 | 2079 | 0.050 |
Why?
|
| Triazoles | 1 | 2009 | 905 | 0.050 |
Why?
|
| Pyrazines | 1 | 2009 | 1206 | 0.050 |
Why?
|
| Government | 1 | 2024 | 162 | 0.050 |
Why?
|
| Tendon Injuries | 1 | 2006 | 329 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2015 | 3265 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3590 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 1813 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2119 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2012 | 1923 | 0.050 |
Why?
|
| Potassium | 1 | 2006 | 1319 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 4 | 2013 | 7451 | 0.050 |
Why?
|
| Sulfasalazine | 1 | 2002 | 85 | 0.050 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 2028 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3038 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2008 | 4567 | 0.050 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 2258 | 0.050 |
Why?
|
| Internet | 1 | 2014 | 3123 | 0.050 |
Why?
|
| Lactones | 1 | 2004 | 316 | 0.050 |
Why?
|
| Swine | 1 | 2012 | 5996 | 0.050 |
Why?
|
| Demography | 1 | 2006 | 1643 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2006 | 2286 | 0.050 |
Why?
|
| Pravastatin | 2 | 2000 | 393 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5442 | 0.050 |
Why?
|
| Drug Costs | 2 | 2015 | 1196 | 0.050 |
Why?
|
| Information Systems | 1 | 2023 | 397 | 0.050 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2022 | 104 | 0.050 |
Why?
|
| Communication | 1 | 2015 | 3910 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2012 | 2190 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2002 | 233 | 0.040 |
Why?
|
| Hemolysis | 2 | 2013 | 419 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 10647 | 0.040 |
Why?
|
| Hand | 1 | 2005 | 907 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 10125 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2016 | 8538 | 0.040 |
Why?
|
| Sample Size | 1 | 2023 | 851 | 0.040 |
Why?
|
| Heart Failure | 2 | 2015 | 11857 | 0.040 |
Why?
|
| Time Factors | 5 | 2016 | 40271 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 794 | 0.040 |
Why?
|
| Patient Selection | 3 | 2016 | 4266 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2007 | 4041 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2005 | 2362 | 0.040 |
Why?
|
| Illinois | 1 | 1998 | 120 | 0.040 |
Why?
|
| Causality | 1 | 2004 | 1255 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2260 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 681 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3837 | 0.040 |
Why?
|
| Casts, Surgical | 1 | 1999 | 184 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 1891 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2000 | 644 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4615 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 1999 | 148 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2004 | 1249 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 3412 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2012 | 3463 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2006 | 1988 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2601 | 0.030 |
Why?
|
| United Arab Emirates | 1 | 2015 | 42 | 0.030 |
Why?
|
| Drug Therapy | 1 | 1998 | 504 | 0.030 |
Why?
|
| Botulinum Toxins, Type A | 1 | 1999 | 238 | 0.030 |
Why?
|
| Liver | 2 | 2008 | 7575 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2015 | 212 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 256 | 0.030 |
Why?
|
| Clarithromycin | 1 | 2015 | 87 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 248 | 0.030 |
Why?
|
| Russia | 1 | 2015 | 386 | 0.030 |
Why?
|
| Familial Mediterranean Fever | 1 | 2015 | 65 | 0.030 |
Why?
|
| California | 2 | 2009 | 1444 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 491 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 1999 | 478 | 0.030 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 1992 | 255 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 2010 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2006 | 3050 | 0.030 |
Why?
|
| Leg | 1 | 1999 | 1089 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 3854 | 0.030 |
Why?
|
| Professional Practice | 1 | 2015 | 314 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 853 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 587 | 0.030 |
Why?
|
| New Jersey | 1 | 2013 | 295 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 882 | 0.030 |
Why?
|
| Israel | 1 | 2015 | 726 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 766 | 0.030 |
Why?
|
| Centrifugation | 1 | 2013 | 122 | 0.030 |
Why?
|
| Biostatistics | 1 | 2014 | 165 | 0.030 |
Why?
|
| Safety | 2 | 2009 | 1159 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 360 | 0.030 |
Why?
|
| Legislation, Drug | 1 | 2014 | 216 | 0.030 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 264 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2002 | 5532 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2008 | 2596 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 389 | 0.020 |
Why?
|
| Brazil | 1 | 2015 | 1247 | 0.020 |
Why?
|
| Japan | 1 | 2015 | 1418 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12875 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1992 | 247 | 0.020 |
Why?
|
| HIV-1 | 1 | 2008 | 6966 | 0.020 |
Why?
|
| Curriculum | 1 | 2024 | 3778 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2015 | 1421 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 4572 | 0.020 |
Why?
|
| Systole | 1 | 1992 | 938 | 0.020 |
Why?
|
| Magnetics | 1 | 2013 | 599 | 0.020 |
Why?
|
| Canada | 1 | 2015 | 2143 | 0.020 |
Why?
|
| Diastole | 1 | 1992 | 784 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1996 | 1193 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 1727 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 6978 | 0.020 |
Why?
|
| Mitolactol | 1 | 1988 | 13 | 0.020 |
Why?
|
| China | 1 | 2015 | 2398 | 0.020 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 1989 | 59 | 0.020 |
Why?
|
| India | 1 | 2015 | 2323 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2015 | 1575 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 1992 | 899 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2024 | 4841 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2015 | 634 | 0.020 |
Why?
|
| Bleomycin | 1 | 1988 | 495 | 0.020 |
Why?
|
| Obesity | 2 | 2008 | 13065 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 2008 | 122 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2022 | 12813 | 0.020 |
Why?
|
| Men's Health | 1 | 2007 | 75 | 0.020 |
Why?
|
| Vinblastine | 1 | 1988 | 488 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13655 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1991 | 521 | 0.020 |
Why?
|
| Birth Weight | 1 | 2015 | 2117 | 0.020 |
Why?
|
| Time | 1 | 2008 | 546 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 475 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1988 | 560 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 793 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1322 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1992 | 2229 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6537 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2008 | 15880 | 0.020 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 152 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 11206 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2008 | 676 | 0.010 |
Why?
|
| Equipment Design | 1 | 2012 | 3530 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 169418 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1960 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 8051 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 7134 | 0.010 |
Why?
|
| Cisplatin | 1 | 1988 | 1661 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2008 | 1081 | 0.010 |
Why?
|
| Hospitals | 1 | 1996 | 3906 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8753 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2006 | 555 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15965 | 0.010 |
Why?
|
| Estrogens | 1 | 2008 | 1531 | 0.010 |
Why?
|
| Sulfones | 1 | 2004 | 448 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6278 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 1359 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 134 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1989 | 1468 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 588 | 0.010 |
Why?
|
| Electroencephalography | 2 | 1992 | 6309 | 0.010 |
Why?
|
| Heart | 1 | 1992 | 4451 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2001 | 692 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1992 | 5620 | 0.010 |
Why?
|
| Muscle Spasticity | 1 | 1999 | 158 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 2483 | 0.010 |
Why?
|
| Life Style | 1 | 2009 | 3929 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2279 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1999 | 336 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2001 | 633 | 0.010 |
Why?
|
| Lovastatin | 1 | 1997 | 115 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2013 | 4737 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3324 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14728 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 1207 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4419 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 7863 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1995 | 158 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1999 | 1585 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10865 | 0.010 |
Why?
|
| Simvastatin | 1 | 1997 | 346 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 1518 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 2007 | 7956 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2000 | 1599 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20231 | 0.010 |
Why?
|
| Patient Admission | 1 | 2001 | 1370 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1995 | 569 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 6242 | 0.010 |
Why?
|
| Gait | 1 | 1999 | 822 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4941 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 11249 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 3577 | 0.010 |
Why?
|
| AIDS Dementia Complex | 1 | 1992 | 154 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 9099 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 7064 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2000 | 2696 | 0.010 |
Why?
|
| Melanoma | 1 | 1988 | 5740 | 0.010 |
Why?
|
| Documentation | 1 | 1995 | 913 | 0.010 |
Why?
|
| Decision Making | 1 | 2002 | 3961 | 0.000 |
Why?
|
| Rheumatic Heart Disease | 1 | 1989 | 164 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1988 | 11843 | 0.000 |
Why?
|
| Spinal Cord Compression | 1 | 1989 | 234 | 0.000 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 963 | 0.000 |
Why?
|
| Observer Variation | 1 | 1992 | 2622 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1991 | 36840 | 0.000 |
Why?
|
| Neck | 1 | 1989 | 736 | 0.000 |
Why?
|
| Quality of Life | 1 | 2004 | 13497 | 0.000 |
Why?
|
| Mitral Valve | 1 | 1989 | 1473 | 0.000 |
Why?
|
| Aortic Valve | 1 | 1989 | 1968 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 20762 | 0.000 |
Why?
|
| Brain | 1 | 1991 | 27438 | 0.000 |
Why?
|